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ABSTRACT
Epigenomic alterations have been associated with both pathogenesis and 
progression of cancer. Here, we analyzed the epigenome of two high-risk APL (hrAPL) 
patients and compared it to non-high-risk APL cases. Despite the lack of common 
genetic signatures, we found that human hrAPL blasts from patients with extremely 
poor prognosis display specific patterns of histone H3 acetylation, specifically 
hyperacetylation at a common set of enhancer regions. In addition, unique profiles 
of the repressive marks H3K27me3 and DNA methylation were exposed in high-risk 
APLs. Epigenetic comparison with low/intermediate-risk APLs and AMLs revealed 
hrAPL-specific patterns of histone acetylation and DNA methylation, suggesting these 
could be further developed into markers for clinical identification. The epigenetic drug 
MC2884, a newly generated general HAT/EZH2 inhibitor, induces apoptosis of high-
risk APL blasts and reshapes their epigenomes by targeting both active and repressive 
marks. Together, our analysis uncovers distinctive epigenome signatures of hrAPL 
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patients, and provides proof of concept for use of epigenome profiling coupled to 
epigenetic drugs to ‘personalize’ precision medicine.
INTRODUCTION
Acute promyelocytic leukemia (APL) is a subtype 
of acute myeloid leukemia (AML) and accounts for ~10% 
of all AML cases. APL is most often characterized by the 
chromosomal translocation t(15;17) that fuses the PML 
gene on chromosome 15 to the retinoic acid receptor 
α (RARA) gene on chromosome 17 resulting in the 
transcription of the PML-RARA oncofusion protein [1, 2]. 
The PML-RARA fusion has been reported to be present in 
>95% of APL cases [1, 3]. In normal cells, PML regulates 
a wide range of proteins including transcription factors 
and ensures normal functioning of biological processes 
such as DNA damage response and microorganism 
resistance [4], while RARA-involved pathways are critical 
for terminal differentiation of myeloid cells [5]. The 
formation of the PML-RARA oncofusion protein disrupts 
normal functioning of both fusion partners expressed by 
wild-type alleles [6] and induces a maturation block at the 
promyelocytic stage [7].
The PML-RARA oncofusion protein has been 
proposed to recruit epigenetic modifiers, like histone 
deacetylase complexes such as SMRT [8] and N-CoR 
[9], DNA methyltransferases [10], and the repressive 
histone methyltransferases SUV39HI [11] and PRC2 [3], 
to provoke alterations in chromatin structure. Genome-
wide analyses revealed that the majority of PML-RARA 
binding sites have low histone H3 acetylation [12–14], 
suggesting a main role for histone deacetylases in PML-
RARA leukemogenesis. 
Although the PML-RARA fusion event is a major 
driving force in APL, the treatment of APL patients is 
clinically different according to risk classification. In 
general, APL can be subdivided into three risk categories 
based on white blood cell (WBC) and platelet count. Low 
risk APL patients have a WBC count lower than 10,000/µL 
and a platelet count over 40,000/µL, intermediate-risk 
APL patients carry a WBC count under 10,000/µL but 
a platelet count lower than 40,000/µL, while high-risk 
APL patients have a WBC count >10,000/µL. Despite 
significant advances in the treatment of APL, the category 
of high-risk APL still poses pressing challenges. 
Pharmacological doses of All-trans retinoic acid 
(ATRA) and/or arsenic trioxide (ATO) are widely used 
by clinicians in treating low- and intermediate-risk APL 
patients [15, 16]. ATO and ATRA act on PML and RARA, 
respectively, and promote degradation of the PML-
RARA oncofusion protein. ATRA adopts the proteasome-
mediated pathway [17] and caspases [18] to degrade PML-
RARA, and ATO induces sumoylation of the PML moiety 
[19]. Depletion of the PML-RARA oncofusion protein 
leads to loss of recruitment of epigenetic repressors and 
remodels the repressive chromatin environment at PML-
RARA binding sites, creating a more accessible chromatin 
state [13]. In contrast to low/intermediate-risk APL 
patients, high-risk APL patients generally show a higher 
relapse rate, and are currently often treated with cytotoxic 
chemotherapy in combination with ATRA/ATO [20]. 
By performing an in-depth transcriptomic and 
epigenomic analysis, we aimed to gain further insights 
into these high-risk APLs (hrAPLs) that might ultimately 
help in improving their prognosis. We used ChIP-seq to 
identify H3K4me1, H3K4me3, H3K27ac, H3K9/14ac, 
H3K27me3, and H3K36me3 enriched regions in patient 
blasts from two high-risk APLs, and also conducted 
whole-genome-bisulfite sequencing (WGBS) and RNA-
seq to probe DNA methylation and gene expression 
profiles, respectively. We compared the epigenomes of 
high-risk APL samples with non-high-risk APL samples 
as well as with other progenitor cells from the normal 
myeloid compartment, revealing a hyperacetylation 
signature at a defined set of enhancer regions in hrAPLs. 
As we also uncovered hrAPL-specific alterations for 
H3K27me3, our analysis suggested that a combination of 
epigenetic drugs that affects acetyltransferase and H3K27 
methyltransferase activity might be beneficial. Using 
the novel HAT/EZH2 inhibitor MC2884 confirmed that 
altering these hrAPL-specific epigenomic features could 
indeed significantly inhibit cell growth.
RESULTS 
The genomic spectrum of two high-risk APLs
To investigate the molecular determinants of high-
risk APLs, we analyzed the genome and epigenome of two 
rare primary APL samples of patients that were resistant 
to standard ATRA plus chemo treatment and presented 
extremely high white blood cell counts (>10,000/µL) 
(Figure 1A). We confirmed transcription of the PML-
RARA fusion in both samples, which revealed expression 
of the BCR2 isoform in patient 7 (pt#7) and BCR1 in 
patient 8 (pt#8) (Figure 1B). In addition, we used SNP 
calls inferred from WGBS data to look for common gene 
variants in the RARA moiety of the two hrAPLs, that 
could potentially explain the absence of an ATRA response 
[21–24]. We found one rare gene variant signature with 
minor allele frequency (MAF) <0.007 in our two hrAPL 
samples, but as this variant was synonymous it was not 
expected to have functional effects on the RARA moiety. 
To examine the full mutational landscape of the 
two hrAPL patients, we used variant calls from WGBS 
as our primary calls and applied additional thresholds of 
read depth (DP) ≥20 and Phred score ≥40. To have more 
confidence in our variant calls, we confirmed these calls 
using RNA-seq and/or ChIP-seq profiles of these two 
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samples. Next, we looked for only missense variants and 
evaluated them using the CHASM program (http://www.
cravat.us/), on a cut-off of MAF ≤0.05, which resulted in 
the identification of a range of mutations. Specifically, the 
analysis identified several candidate driving mutations 
such as TET2 and BRCA2, but none of them was recurrent 
in the two patients (Figure 1C).
A hyperacetylation signature typifies PML-
RARA binding sites in high-risk APLs 
Given the absence of common secondary mutations, 
we focused on the epigenomic patterns observed in the two 
hrAPL patients and explored whether an ATRA response 
was still observed at the epigenetic level as compared 
to low/intermediate-risk APLs. The APL-associated 
oncofusion protein PML-RARA is able to recruit HDACs 
and establish a hypoacetylated chromatin signature, 
which can be alleviated by ATRA-induced PML-RARA 
degradation [13]. Hence, we first surveyed binding of 
PML-RARA in hrAPLs by ChIP-seq using an antibody 
against PML (the non-DNA-binding moiety of the PML-
RARA fusion). Our analysis revealed occupancy of PML-
RARA at previously identified high-confidence PML-
RARA binding sites (n = 2,723) (Figure 2A) from the 
NB4 model cell line and low/intermediate-risk APLs [13], 
such as the TGM2 and ID1 genomic regions (Figure 2B). 
We generated additional epigenetic ChIP-seq profiles 
using ex vivo ATRA treated patient cells and examined 
epigenetic alterations at the same PML-RARA binding 
sites. This confirmed elevated histone H3 acetylation 
levels after PML-RARA depletion by ATRA treatment at 
the TGM2, RARB, ASB2 and ID1 loci (Figure 2C). Next, 
we further delved into global ATRA response at all 2,723 
PML-RARA occupancy loci and found that generally 
H3K9/14ac levels increased in an ATRA-treatment-
dependent manner in hrAPLs (pt#7 and pt#8) (Figure 2D). 
Interestingly, we noted significantly elevated steady-state 
levels of histone acetylation at PML-RARA binding sites 
in hrAPLs as compared to low/intermediate-risk APL 
(pt#9) (Figure 2D) in both control and ATRA-treated 
samples, suggesting that abnormal hyperacetylation at 
PML-RARA binding sites might be a crucial property of 
high-risk APLs. 
Figure 1: Genomic analysis of two high-risk APLs (hrAPLs). (A) Schematic depiction of the experimental setup and analysis 
workflow for two hrAPLs. (B) Overview of the PML-RARA isoforms expressed in patient #7 (pt#7) and #8 (pt#8). (C) Diagram of the 
analysis workflow to identify genomic variants in the two low OS APLs #7 and #8. The table depicts the top candidate genetic variants 
identified in pt#7 and pt#8. 
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Hyperacetylation at enhancer and promoter 
regions in high-risk APLs
To analyze whether increased acetylation 
(H3K9/14ac and H3K27ac) was a genome-wide feature, 
we identified all active hrAPL promoter and enhancer 
regions based on levels of the promoter mark H3K4me3 
or the enhancer mark H3K4me1 in association with 
H3K27ac (Figure 3A). A total of 9,349 common active 
promoters (high H3K4me3 and H3K27ac, low H3K4me1 
and H3K27me3) and 10,208 common active enhancers 
(high H3K4me1 and H3K27ac, low H3K4me3 and 
H3K27me3) were detected. In line with the positive 
correlation between histone H3 acetylation levels and 
gene expression, we observed that associated genes of 
active promoters and enhancers are expressed, but also 
that these target genes seem higher expressed in hrAPLs 
as compared to APL (Figure 3B). To further explore 
whether elevated acetylation levels are common, we 
compared H3K9/14ac intensity for all active promoter 
and enhancer regions in two hrAPLs and two APLs. 
Our findings revealed increased H3K9/14ac levels at the 
two types of regions in hrAPLs as compared to APLs 
(Figure 3C), suggesting the hyperacetylation signature is 
not only present at PML-RARA binding sites, but even is 
a ubiquitous mark at other regulatory elements.
As the difference in histone H3 acetylation was 
most obvious at putative enhancer regions, we examined 
whether these regions might represent an activation 
signature of a unique cellular population. For this, 
we compared the H3K27ac occupancy landscape of 
hrAPLs with those of five progenitor cells from healthy 
individuals including normal CD34+ cells, promyelocytes, 
metamyelocytes, band neutrophils and segmented 
neutrophils. This revealed distinct global acetylation 
levels at the hrAPL enhancer sites in different progenitor 
population (Figure 3D), but no similar enrichments as 
observed in hrAPLs, suggesting that the hyperacetylation 
signature present in hrAPLs is not reminiscent of a specific 
progenitor population.
To determine enriched consensus sequences at all 
active enhancers with the hyperacetylation signature in 
hrAPLs (Figure 3C), we conducted motif screening. This 
discerned significant enrichment for RUNX1 and ETS 
Figure 2: Epigenomic analysis of high-risk APLs (hrAPLs). (A) Heatmap of PML tag density at PML-RARA binding sites ± 10 
kb, after PML ChIP-seq in one APL (pt#79) and one hrAPL (pt#8). (B) Genome browser screenshot of PML ChIP-seq results at the TGM2 
and ID1 locus. (C) Overview of APL ChIP-seq (H3K27ac, H3K4me1, H3K9/14ac) data at the genomic regions of the TGM2, RARB, ASB2 
and ID1 genes before and after ex vivo ATRA treatment. (D) Boxplot showing changes in H3K9/14ac before and after ex vivo treatment with 
ATRA at PML-RARA binding sites in one APL and two hrAPLs. * indicates significance at p < 0.01 using the Wilcoxon Signed-Rank test. 
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consensus motifs (Figure 3E), implying transcription 
factors belonging to these families might assist in 
epigenetic marking of these regions.
Finally, we asked whether the hyperacetylation state 
at identified enhancers is specific for hrAPLs. For this, we 
compared the hrAPL H3K27ac pattern with levels of 27 
AMLs with varying prognosis and cytogenetic background 
[25]. In order to get unbiased and precise results, we 
included 4 additional high-risk APLs (pt#A to D; number 
of leukocytes >10,000/µL) and 1 low-risk APL (pt#E). 
Indeed, acetylation levels at the set of hrAPL enhancers 
are increased as compared to acetylation at these regions 
in almost any other subtype of AML (p < 0.01 for pairwise 
comparisons) (Figure 3F), implying that the acetylation 
Figure 3: The histone acetylation signature in high-risk APLs (hrAPLs). (A) Heatmap of histone modification (H3K27ac, 
H3K4me1, H3K4me3 and H3K27me3) densities at promoter and enhancer regions defined in hrAPL #7 and #8. (B) Boxplot showing 
expression of genes associated with active promoter (top) and enhancer (bottom) regions defined in two hrAPLs (pt#7 and pt#8) and one 
APL (pt#9). (C) Heatmap of H3K9/14ac densities at active promoter and enhancer regions defined in two hrAPLs (pt#7 and pt#8) and two 
APLs (pt#74 and pt#164). (D) Boxplot showing H3K27ac levels of one primary APL (pt#9), 2 hrAPLs (pt#7 and pt#8), normal CD34+ cells 
and normal neutrophil progenitor populations (promyelocytes, metamyelocytes, band neutrophils and segmented neutrophils) at enhancer 
regions defined in hrAPLs. *p < 0.01 for all pairwise comparisons between hrAPLs and other APLs/progenitors. (E) Motifs enriched at 
enhancer regions identified in hrAPLs as compared to random regions of equal size with similar nucleotide composition and a random set 
of ENCODE defined enhancers. (F) Boxplot showing H3K27ac levels of primary APLs, hrAPLs and 27 AMLs with a different genetic 
status at enhancer regions defined in hrAPLs. *p < 0.01 for all pairwise comparisons between hrAPLs and other APLs/AMLs, excluding 
comparisons with AML pt#37. 
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signature might be used to identify this particular subclass 
of APLs. 
To allow clinical discrimination of this subset using 
assays that are sequencing-independent, we defined the 
most differential acetylated regions. Using an FDR <0.01 
and p-value < 0.0002, we identified 22 regions specifically 
acetylated in hrAPLs that could potentially be used for 
clinical subtype stratification (Supplementary Table 1), 
although these results will need further confirmation in a 
larger cohort of hrAPLs.
Altogether these results reveal that the histone 
acetylation landscape of hrAPLs is different as compared 
to low/intermediate-risk APLs and myeloid progenitors, 
and generally represents a hyperacetylated histone 
signature.
Deregulation in repressive histone methylation 
impacts on APLs with low overall survival 
APL leukemogenesis has also been linked to 
H3K27me3 alterations [3, 13], suggesting an important 
role for those genomic regions occupied by the PRC2 
complex and H3K27me3 in APL. We speculated that in 
hrAPLs, the hyperacetylated signature might affect the 
presence of repressive marks, especially H3K27me3 given 
the mutual exclusivity of acetylation and methylation on 
the same lysine. Inspecting H3K27me3 patterns in hrAPLs 
and APL revealed differential occupancy at a number of 
loci, for example, H3K27me3 hypermethylation at the 
ZSCAN12/GPX6 genomic region (Figure 4A, 4B), but 
mainly hypomethylation at other (n = 214) differential 
Figure 4: H3K27me3 alterations in high-risk APLs (hrAPLs). (A) Heatmap of H3K27me3 levels on differential regions between 
primary APL (pt#9) and hrAPL (pt#7 and pt#8) samples. (B) Overview of H3K27ac, H3K36me3 and H3K27me3 levels at the ZSCAN12 
genomic region in one primary APL and two hrAPL samples. 
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H3K27me3 regions in hrAPLs. These results indicate that 
besides H3 acetylation also other epigenetic features such 
as H3K27me3 are altered in hrAPL and likely affect the 
transcriptional program. 
High-risk APLs harbor an altered DNA 
methylation signature
Next, we assessed whether hrAPL and APLs 
presented differential global CpG methylation patterns. To 
extend our dataset, we included DNA methylation data of 
a cohort of 13 APL patients (450 K, from TCGA; [26]), of 
which 3 had an exceptionally high white blood cell count 
(>10,000/µL) and survival below 1 month that could be 
integrated as hrAPL cases (Figure 5A, 5B).
Supervised clustering to identify differential CpG 
methylation sites between hrAPLs and APLs revealed a 
set of 1,817 CpGs that could classify APLs into the high- 
or low/intermediate-risk category (Figure 5C). These 
included 399 hypomethylated CpG regions (CpG coverage 
>4 and p-value < 0.005) which displayed enriched 
H3K4me3 and H3K27ac levels in hrAPLs (Figure 5D), 
and 1,418 hypermethylated CpG regions. To further 
validate this finding, we integrated all DNA methylation 
data from TCGA AML samples [26]. This indicated that 
the unique hyper/hypo methylation signature discovered 
for hrAPLs is specific (Figure 5E, top). Importantly, 
this signature could be further filtered to 23 CpGs (CpG 
coverage > 4, p-value < 0.0007) (Supplementary Table 2; 
Figure 5E, bottom), which could distinguish hrAPLs from 
all APLs/AMLs. 
To validate this signature, we examined methylation 
levels reported for high-, intermediate- and low-risk APLs 
in a separate study [27]. This showed that 3 out of 4 
regions with sufficient coverage were hypomethylated in 
high-risk cases as compared to low/intermediate-risk APLs 
(Figure 5F). These results suggest that the 23 CpG hrAPL 
signature potentially enables PCR-based approaches 
to identify the hrAPL subtype at diagnosis. As for the 
identified Histone H3 acetylation signature above, further 
confirmation in a larger cohort of hrAPLs will be needed.
MC2884 induces apoptosis in hrAPLs and 
remodels the epigenome
Since hrAPLs display multiple epigenome 
deregulations, we wondered whether a multi epi-drug 
approach targeting HATs and PRC2 would be beneficial. 
We identified MC2884, a novel HAT/EZH2 inhibitor 
(Petraglia et al., in press), as a promising candidate. We 
evaluated MC2884-induced apoptosis in the hrAPLs 
(pt#7 and pt#8) as well as in an ATRA-sensitive APL 
(pt#9) after 24 hours ex vivo treatment. Our results show 
that the hrAPLs did not undergo efficient apoptosis (as 
measured by the % of cells in the pre-G1 phase) ex vivo in 
response to HDACi’s such as SAHA or MS275 [28], when 
compared to ATRA-sensitive blasts (pt#9). In contrast, ex 
vivo MC2884 treatment in hrAPLs was accompanied by 
remarkable apoptosis induction (Figure 6A).
As the hrAPLs harbor an aberrant H3K27ac, 
H3K9/14ac and H3K27me3 signature, we inquired whether 
MC2884 would reset acetylation and H3K27me3 patterns 
and thereby trigger the onset of apoptosis. We therefore 
treated pt#8 blasts with MC2884 ex vivo for 4 and 24 h, and 
examined H3K27ac and H3K27me3 levels. We identified 
3,636 H3K27ac regions (Figure 6B) for which occupancy 
was changed (FC > 3×STDEV, % gain, % loss), such as at 
the BCL2, SEC23 and AK2 genomic regions (Figure 6C). 
Amongst the changed regions, 1,387 represented enhancer 
regions decreased in H3K27ac (Figure 6D). Functional 
annotation of these decreased enhancer regions revealed 
enrichment for genes associated with AML, PML-RARA 
binding, JAK/STAT signaling, Toll-like receptor signaling, 
and the RAS pathway (Figure 6E).
In addition to H3K27ac changes, we observed 799 
H3K27me3 regions for which occupancy was changed 
(FC > 3×STDEV, % gain, % loss) (Figure 6F), suggesting 
that MC2884 treatment might alter the function of histone 
H3 lysine 27 both by reducing acetylation at this residue 
as well as methylation. Interestingly, reduced H3K27ac 
was also observed at a putative enhancer region of EZH2 
(Figure 6G), suggesting that MC2884-chromatin action 
also affects EZH2 gene transcription and further changes 
polycomb complex localization. Indeed, expression of 
EZH2 was reduced, similar as for other genes associated 
with reduced enhancer acetylation (Figure 6H, left). In 
contrast, genes associated with reduction in H3K27me3 
increased in expression (Figure 6H, right). Together, 
these results reveal that MC2884 treatment reshapes the 
epigenome of hrAPLs and increases apoptosis.
DISCUSSION
Treatment of APL has significantly advanced 
over the last decade due to increased knowledge on the 
molecular mechanisms underlying APL pathogenesis and 
the widespread application of ATRA and arsenic trioxide 
(ATO) in treatment protocols. While low/intermediate-risk 
APL patients have benefited from these developments, 
especially the reduced usage of chemotherapy, clinical 
therapy for high-risk APL patients often still include 
cytotoxic chemotherapy [20]. Here, by performing an in-
depth transcriptomic and epigenomic analysis, we aimed 
to point out major causes of severe drug resistance in these 
high-risk APLs (hrAPLs) and identify entry points for the 
application of epi-drugs. 
As no common genetic signature could be identified 
by our genomic scan, we focused on the epigenomic 
comparison between high-risk and low/intermediate-
risk APL samples. Our findings revealed hrAPL-specific 
alterations in histone acetylation, H3K27me3 and DNA 
methylation. Given these specific epigenomic features, 
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Figure 5: DNA methylation characteristics in high-risk APLs (hrAPLs). (A) White blood cell counts in 13 APL cases described 
and analyzed in Ley et al., 2012. [26] (B) Event Free Survival (EFS) and Overall Survival (OS) in 13 APL cases described and analyzed 
in Ley et al., 2012. [26] (C) Supervised clustering of DNA methylation patterns using 5 hrAPLs and 10 APLs. (D) Heatmap of histone 
modification density at the two clusters defined in (C). (E) (Top) DNA methylation patterns of 181 AMLs over the two APL clusters 
defined in Figure (C). (Bottom) DNA methylation patterns using 181 AML and 15 APLs over 23 CpGs hypomethylated in hrAPLs. (F) 
DNA methylation level of high-risk and low/intermediate-risk APLs [27] at 4 regions overlapping with the 23 CpG DNAme signature 
identified in this study.
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we tried to establish hrAPL-specific epigenetic signatures 
that could potentially be used as biomarker. For histone 
acetylation, we identified 22 hyperacetylated regions that 
seemed to be hrAPL-specific, and for DNA methylation 
we proposed a signature of 23 CpGs that distinguishes 
hrAPLs from other APLs/AMLs. Additional samples 
and confirmation in different cohorts will be needed to 
support these regions as real biomarkers. Nevertheless, it 
suggests that histone acetylation level has similar potential 
to classify samples as DNA methylation signatures.
The prominent signature of hyperacetylation of 
histones at a set of defined promoters and enhancers in 
high-risk APLs suggests a more open chromatin structure 
in hrAPLs. The hyperacetylation signature was also 
observed at PML-RARA binding sites, which seemed 
counterintuitive given the previously reported recruitment 
of histone deacetylases by us and others [8, 9, 13, 29]. 
Moreover, it is surprising that despite a hyperacetylation 
signature at PML-RARA binding sites, histone acetylation 
is still increased upon ATRA treatment. Previously, we 
have shown that for another AML associated fusion 
protein (AML1-ETO) both acetyltransferase and 
deacetylase enzymes are present at its binding site [30]. 
This could well be the case in this situation as we already 
previously reported the acetyltransferase p300 might 
be present at PML-RARA binding sites [31] to mediate 
histone acetylation. Maybe through stabilization of its 
binding or increased activity, hyperacetylation at the 
PML-RARA binding regions is established in hrAPLs. 
However, it can still be expected that also HDACs 
recruited by PML-RARA will be present. These will be 
removed upon ATRA treatment and subsequent PML-
RARA degradation, resulting in an even further increase 
in acetylation. 
Given the hyperacetylation signature and the 
absence of a clear ATRA response (which would even 
further increase acetylation), inhibition of HDAC 
activity which has been previously proposed to treat APL 
[9, 32–36] would likely be ineffective. As we also 
observed other epigenetic alterations in hrAPLs as 
compared to APLs, especially for H3K27me3, our 
analysis suggested that a combination of epigenetic 
drugs that affect histone acetyltransferase and H3K27 
methyltransferase activity might be beneficial. Using 
the novel HAT/EZH2 inhibitor MC2884 confirmed 
that altering these hrAPL-specific epigenomic features 
could indeed inhibit cell growth. These results suggest 
that epigenome-based patient stratification, in this case 
hrAPLs may provide a novel strategy to be coupled 
with genome analyses to “personalize” precision 
medicine.
METHODS
Next generation sequencing (NGS) experiments
Samples for NGS experiments were obtained from 
different laboratories but have been processed similarly, 
with standard operating procedures set by BLUEPRINT 
at the start of the project using extensively validated 
and documented antibody batches and other reagents. 
Moreover, all samples underwent strict quality control at 
different levels (e.g. sequence quality, read depth, visual 
inspection) before they were included in the downstream 
analysis pipeline. The exact procedures and quality filters 
can be found at the BLUEPRINT website (www.blueprint-
epigenome.eu).
Chromatin immunoprecipitation (ChIP) 
ChIP extracts preparation and procedures have been 
carried out following IHEC procedures using Diagenode 
antibodies and as reported [13, 29]. The fold enrichment 
of H3K27ac and H3K27me3 ChIP’ed DNA was evaluated. 
Primer sequences were as follows: BCL2 promoter region 
(at -410 and -282 from +1), forward (5ʹ- GTG TTC CGC 
GTG ATT GAA GAC-3ʹ) and reverse (5ʹ- CAG AGA 
AAG AAG AGG AGT TAT AA-3ʹ); for chr21:44,496,353-
44,496,918/CBS region, forward (5ʹ- CGC AGA ACA 
GTC GCC TTG-3ʹ) and reverse (5ʹ- GTC CAG AGC 
ACG ATG TTT GG-3ʹ); for chr17:4,938,577-4,939,058/
SLC52A1 region, forward (5ʹ- CGA GTT GGA GAG 
GGG AGT G-3ʹ) and reverse (5ʹ- AAC AAA ACC CCA 
GCT GTG TG-3ʹ).
RNA extraction and RT-PCR
Total RNA was extracted with Trizol (Invitrogen) 
and converted into cDNA using VILO (Invitrogen). For 
amplification, the following primers were used: EZH2, 
forward (5ʹ-CATCATAGCTCCAGCTCCCG-3ʹ) and 
reverse (5ʹ-CATCCCGGAAAGCGGTTTTG-3ʹ); EED, 
forward (5ʹ-CGATTTGCGACAGTGGG-3ʹ) and reverse 
Figure 6: MC2884 induces apoptosis in hrAPLs and alters the epigenome. (A) Analysis of cell death (% of cells in pre-G1 
phase) induced by MC2884, HDACi (MS275 and/or SAHA) and ATRA in ex vivo APL blasts (24 h). (B) Heatmap showing H3K27ac 
changes at promoter and enhancer regions upon ex vivo MC2884 treatment of hrAPL (pt#8) cells. (C) Overview of epigenetic changes at 
the BCL2, AK2 and SEC23A genomic regions in control or MC2884 ex vivo treated hrAPL cells. (D) (Left) Boxplot and (Right) heatmap 
showing H3K27ac changes at enhancer regions that show reduced occupancy levels after ex vivo MC2884 treatment of a hrAPL sample. * 
indicates significance at p < 0.01. (E) Table showing functional annotation of genes associated with enhancers that have reduced H3K27ac 
after ex vivo MC2884 treatment of hrAPL (pt#8). (F) Heatmap showing H3K27me3 changes at genomic regions upon ex vivo MC2884 
treatment of hrAPL cells. (G) Overview of H3K27ac at the EZH2 gene in control or MC2884 ex vivo treated hrAPL cells; (H) Expression 
of genes associated with enhancers (distance to gene <50 kb and RPKM sum >100; left) reduced in H3K27ac or of genes associated with 
promoters with reduced H3K27me3 (RPKM sum > 0.5; right). * indicates significance at p < 0.01. 
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(5ʹ-CAGGTGCATTTGGCGTG-3ʹ); SUZ12, forward 
(5ʹ-GTCCTGCTTGTGAAAGTTTGC-3ʹ) and reverse 
(5ʹ-CAAATGTCTTTTCCCCATCCT-3ʹ); BCL2, forward 
(5ʹ-GAACTGGGGGAGGATTGTGG-3ʹ) and reverse 
(5ʹ-CAGCCTCCGTTATCCTGGAT-3ʹ); GAPDH, forward 
(5ʹ-TCAACGGGAAGCCCATCACCA-3ʹ) and reverse 
(5ʹ-ACGGAAGGCCATGCCAGTGA-3ʹ).
Whole-genome bisulfite sequencing 
Genomic DNA (1–2 μg) was spiked with unmethylated 
λ DNA (5 ng of λ DNA per μg of genomic DNA) (Promega). 
The DNA was sheared by sonication to 50–500 bp using a 
Covaris E220 and fragments of size 150–300 bp were selected 
using AMPure XP beads (Agencourt Bioscience Corp.). 
Genomic DNA libraries were constructed using the Illumina 
TruSeq Sample Preparation kit (Illumina Inc.) following the 
Illumina standard protocol: end repair was performed on the 
DNA fragments, an adenine was added to the 3ʹ extremities 
of the fragments and Illumina TruSeq adapters were ligated 
at each extremity. After adaptor ligation, the DNA was treated 
with sodium bisulfite using the EpiTexy Bisulfite kit (Qiagen) 
following the manufacturer’s instructions for formalin-fixed 
and paraffin-embedded (FFPE) tissue samples. Two rounds 
of bisulfite conversion were performed to assure a high 
conversion rate. An enrichment for adaptor-ligated DNA 
was carried out through 7 PCR cycles using the PfuTurboCx 
Hotstart DNA polymerase (Stratagene). Library quality was 
monitored using the Agilent 2100 BioAnalyzer (Agilent), and 
the concentration of viable sequencing fragments (molecules 
carrying adaptors at both extremities) estimated using 
quantitative PCR with the library quantification kit from 
KAPA Biosystem. Paired-end DNA sequencing (2 × 100 
nucleotides) was then performed using the Illumina Hi-Seq 
2000.
The data are publicly available and can be accessed 
via the Blueprint DCC: http://dcc.blueprint-epigenome.
eu/#/experiments.
Peak calling and identification of promoter and 
enhancer regions
For peak calling the BAM files were first filtered 
to remove the reads with mapping quality less than 
15, followed by fragment size modeling (http://code.
google.com/p/phantompeakqual-tools/). The peak-
calling algorithm MACS2 (http://github.com/taoliu/
MACS/) was used to detect the binding sites for the 
three studied histone marks at default q-value (5.00e-02). 
H3K4me1 peaks were called using the broad setting of 
MACS2 while peaks for marks H3K27ac, H3K4me3 and 
transcription factor PML-RARA were called using the 
default (narrow) setting.
In order to identify promoter and enhancer regions, 
non-overlapping H3K4me3 and H3K4me1 bound regions 
were taken into account, respectively. The common 
promoter and enhancer regions across the hrAPL samples 
were computed using the in-house script intersectbed. 
pl. Further, normalized tag enrichment for H3K27ac and 
H3K27me3 was used to mark active and inactive promoter 
and enhancer regions. Also, normalized tag enrichment for 
H3K27ac and H3K9/14ac in common enhancer regions 
was used to compute differentially active regions across 
different samples (pt#7, pt#8 and pt#9) and cell types 
(CD34+, promyelocytes, metamyelocytes, band neutrophils 
and segmented neutrophils). The intensity graphs were 
generated using the in-house script makeColorprofiles.pl. 
Discriminating hyperacetylated regions were identified 
using DESeq package (http://bioconductor.org/packages/
release/bioc/html/DESeq.html) and selection for regions 
with an FDR < 0.01 and p-value < 0.0002 between hrAPL 
and all other samples (APL and AML). Motif analysis was 
performed as before [30].
The data are publicly available and can be accessed 
via the Blueprint DCC: http://dcc.blueprint-epigenome.
eu/#/experiments.
RNA-seq alignment and expression analysis
RNA-seq reads were aligned using GSNAP [37] 
using non-default parameters -m 1 - N 1 -n 1 -Q -s 
Ensembl_splice_68. RNA-seq library data was initially 
subjected to a quality control step, where, based on read 
distribution over the annotated genome, libraries that 
are outliers were identified and discarded from further 
analysis. For expression analyses, reads were aligned to 
the Ensembl v70 (GRCh37.70) human transcriptome using 
Bowtie. Quantification of gene expression was performed 
using MMSEQ [38].
The data are publicly available and can be accessed 
via the Blueprint DCC: http://dcc.blueprint-epigenome.
eu/#/experiments.
SNP calling and identification of potential 
functional SNPs
SNP calls were identified using the CNAG in-house 
pipeline based on WGBS data. The list of variant calls was 
reduced by applying a number of filters, starting from the 
number of tags (≥20) and Phred score (≥40) on the SNP 
calls from WGBS. The reduced list was then given as an 
input to the CHASM web server (http://www.cravat.us/ 
version 3.1) for functional annotation and only the missense 
variants present in driver genes (as identified by Vogelstein) 
[39] at MAF ≤ 5% (1000 G) were selected. Further, only 
the variants reported in ChIP-seq and RNA-seq tracks by 
applying computational tools samtools (mpileup option) 
and GATK along with the variations confirmed through 
visual inspection of the tracks using IGV were selected.
The data are publicly available and can be accessed 
via the Blueprint DCC: http://dcc.blueprint-epigenome.
eu/#/experiments.
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Identification of signature methylation regions 
Cytosine methylation level was called for every 
cytosine site in different sequence contexts such as CHH, 
CXG and CG (H denotes A, T, or C and X denotes A or 
T). Due to the fact that symmetric methylation level is 
the common case for CG methylation, we focused on CG 
methylation and excluded non-CpG methylation for further 
analysis. Within a symmetric CG context, CG pairs on both 
forward and reverse strands were combined and a CpG 
coverage threshold of ≥5 was used. Further, the methylation 
samples pt#7 and pt#8 were grouped together with the 3 
APL samples of low OS from TCGA [26] and compared 
with the APL samples. We selected the regions for which CG 
methylation was determined across all samples and applied 
the Wilcoxon test to determine statistically significant 
different CpGs between the two groups. A cut-off of the 
p-value of 0.005 was applied as the selection criteria and 
regions were plotted. To identify the most discriminating 
CpGs, we applied the same test at a more stringent cut-off 
p-value of 0.0007. Moreover, only the CpG regions that had 
beta values in all 181 AML samples were selected. 
The metadata of the APL and AML samples can be 
found in Supplementary Table 3.
Cell cycle analysis
For cell cycle analyses, cells were plated (2 × 105 
cells/mL) and after stimulation (performed as indicated 
in the text) were harvested, centrifuged at 1,200 rpm for 
5ʹ and resuspended in 500 μL of a hypotonic solution 
containing 1X PBS, Sodium Citrate 0.1%, 0.1% NP-40, 
RNAase A and 50 mg/mL Propidium Iodide (PI). After 
30’ at room temperature (RT) in the dark, samples were 
acquired by FACS-Calibur (BD Biosciences, San Jose, 
CA, USA) using CellQuest software (BD Biosciences). 
The percentage in different phases of the cell cycle (and 
pre-G1 as a measure of apoptosis) was determined by 
ModFit LT V3 software (Verity). All experiments were 
performed in triplicate.
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